Our finding that karonudib had potent inhibitory effect in lymphoma cells harboring mutated TP53 could be an important discovery, as many drugs used in treatment of relapsed lymphoma patients require a functional TP53 to be effective40–42 and TP53 loss or mutation is associated with inferior survival42–45. Here, TP53 is linked to lymphoma.